September 9th 2025
Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Metabolically Healthy Obesity May Increase Risk of Heart Failure, but Not Heart Attack or Stroke
October 5th 2021EASD 2021: Patients with metabolically healthy obesity are nearly 33% more likely to develop heart failure and atrial fibrillation than healthy persons of normal weight, suggests new analysis.